Lucentis® is approved for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of vision loss in people 50 years or older in the United States. This condition damages the macula, which is located in the center of the retina and enables you to see fine details clearly. You rely on your macula whenever you read, drive, or do other activities that require you to focus on precise details. A person with AMD loses the ability to perceive fine details both up close and at a distance. This vision loss usually affects only your central vision.
There are two types of AMD. About 90% of people with AMD have the atrophic or “dry” form of AMD, which develops when the tissues of the macula grow thin with age. About 10% have the exudative or “wet” form of AMD. With wet AMD, abnormal blood vessels grow underneath the retina. These unhealthy vessels leak blood and fluid, which can scar the macula. Vision loss can be rapid and severe. Lucentis is not effective for the treatment of dry AMD.
Lucentis is also used to treat macular edema that results from central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). The drug may also be used for the treatment of macular edema due to diabetic retinopathy.